Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

Another challenge is brewing for restaurants. It’s not the economy, another global disease, or a weather disaster. It’s the ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the ...